An interventional study of No intervention and hCG + FSH therapy in APHRODITE Group, sponsored by Indira IVF Hospital Pvt Ltd. Not yet recruiting at 8 sites in India. Open to male participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to determine whether short-term gonadotropin therapy (hCG + FSH) can increase sperm availability for ICSI in men with idiopathic non-obstructive azoospermia (NOA) and hypogonadism. The main questions it aims to answer are:
Does hormonal optimization improve the likelihood of obtaining usable sperm (via ejaculate or micro-TESE) by Week 16? Does hormonal therapy reduce the need for micro-TESE or improve downstream embryological and clinical outcomes?
Because there is a comparison group, researchers will compare hCG + FSH hormonal therapy with standard-of-care (no gonadotropins) to see if hormonal optimization increases sperm retrieval success and decreases surgical reliance.
Participants will:
Undergo baseline hormonal and semen testing Be randomized to either hormonal therapy or standard-of-care If in the hormonal arm: receive hCG and FSH with monthly dose titration and aromatase inhibitors if indicated Provide semen samples at Weeks 12 and 16 Undergo micro-TESE if no ejaculated sperm are found (timing per protocol) Complete safety assessments and follow-up through Week 16
283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.
This study's planned enrollment of 860 is above the median of 80 across 188 interventional studies indexed under Infertility, Male.
Browse Infertility, Male studies →Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Idiopathic NOA; hypogonadal (TT \<350 ng/dL on two fasting morning tests); FSH ≥7.6 IU/L (APHRODITE Group 3: 7.6-12.0 IU/L; Group 4: >12.0 IU/L).
Exclusion Criteria:
cryptorchidism, chemo/radiation, genetic NOA (e.g., AZFa/complete AZFb), testicular trauma/torsion, post-orchitis. prior micro-TESE within 12 months; recent gonadotropin therapy (\<6 months); uncontrolled endocrine disease; active ; severe liver disease; polycythemia (Hct>50%); inability to comply. Varicocele>= Grade 3
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: hCG + FSH therapy
Other: No intervention
Standard of Care
hCG + FSH therapy with monthly hormone-driven titration (hCG initial \~83 µg SC twice weekly; no preset min/max; target TT \>350-900 ng/dL) + FSH 150 IU SC twice weekly (increase to 150 IU SC three times weekly if 'FSH reset' \<1.5 IU/L); allow anastrozole 1 mg PO daily /letrozole 2.5 mg half tablet alternate day if T/E \<10
This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Success or Sperm Availability
Sperm Availability for ICSI was defined as the presence of viable sperm suitable for intracytoplasmic sperm injection (ICSI) at any time from randomization through Week 16. Sperm could be obtained either through ejaculate or via microsurgical testicular sperm extraction (micro-TESE). Assessment of sperm availability was performed by a centralized adjudication committee, which was blinded to treatment allocation to ensure objective and unbiased evaluation.
Time frame: from randomization through Week 16 via ejaculate or micro-TESE
Micro-TESE Sperm Retrieval Rate (SSR)
Whether sperm are retrieved during micro-TESE
Time frame: The Micro-TESE Sperm Retrieval Rate (SSR) was assessed during the period from randomization through Week 16. The outcome was determined based on the availability of at least one viable sperm retrieved via microsurgical testicular sperm extraction (micro-
Need for Micro-TESE Surgery
Whether the participant requires micro-TESE
Time frame: Up to Week 16
Safety / Harms
All adverse events (AE/SAE) related to treatment or procedure
Time frame: Week 16
ICSI Fertilization Rate
% of injected oocytes that form normal 2PN embryos
Time frame: Within the ICSI cycle ≈ Day 1-3 after ICSI
Blastulation Rate
% of embryos reaching blastocyst stage
Time frame: Day 5-7 after fertilization
Blastocyst Quality
Grading of blastocysts based on standard morphology criteria
Time frame: Day 5-7 after fertilization
Top-Quality Blastocyst Rate
% of "top-1 quality" blastocysts formed
Time frame: Day 5-7 after fertilization
Clinical Pregnancy Rate
Presence of gestational sac with cardiac activity on ultrasound
Time frame: ≈ 6-8 weeks after embryo transfer
Miscarriage Rate
Pregnancy loss before 20 weeks
Time frame: From pregnancy confirmation to 20 weeks gestation
Live Birth
Delivery of a live infant
Time frame: Up to delivery (~9 months after embryo transfer)
Plan to share: Undecided — will be shared on request
Start is estimated for Jan 2027; primary completion for Nov 2027, 9 months later.
Of 78 non-industry interventional studies with no phase under Infertility, Male, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 9 months is below that.
Counting every sponsor, half of 93 studies reached it within 34 months; a quarter within 17 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Jul 2026 → Jan 2027, primary completion Jan 2027 → Nov 2027 and completion Jul 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Indira IVF Hospital Pvt Ltd